EMDA^®

UNPLANNED UROLOGY VISITS

PEACE OF MIND

BACK CONTROL

EMDA^® field of application

Emda® improves patients‘ quality of life
Safe - the applied electric current causes no biological damage to tissue and no chemical modification of drug
Well tolerated
Deeper drug penetration into the target tissue compared to conventional therapy
Significant reduction in disease recurrence and/or progression
Drug plasma levels remain well below toxic levels
Highly cost-effective
Significant increase in disease-free interval

A urogenic 16F electrode-catheter is inserted into the bladder
The bladder is drained to remove residual electrolytes
The drug solution is administered
Two dispersive electrodes are placed on the sides of the navel with an abundante layer of conductive gel
A micro-current is applied for 20 minutes

Play Video

The Physion EMDA® system has been proved excellent results in treating high-risk and intermediate-risk patients with non-muscle invasive bladder cancer.
EMDA® + Mitomycin treatment is an efficacy tool in the long term conservative strategy of high-risk unresponsive to BCG as a “bladder sparing” therapy.
EMDA® can be used with all type of Mitomycin and in sequential treatment EMDA® + Mitomycin is combined with BCG.
Proven deeper tissue penetration of Mytomicin with EMDA® compared to passive administration.
Several thousand treatment cycles have been performed with complete safety following TURBT: significantly reduced recurrence and progression with increased disease-free interval.
More data on EMDA® now available than any other device assisted drug delivery system available.
In according to EAU Guidelines 2021.

TRADITIONAL THERAPY

EMDA® ENHANCED

Sequential treatment BCG/EMDA® + Mitomycin has an excellent oncologic efficacy and is twice as efficace as the traditional therapy